¥21.00 pre-market 4564.T OncoTherapy Science JPX 24 Jan 2026: Most active, earnings ahead
The most active pre-market name on JPX, 4564.T stock trades at ¥21.00 on 24 Jan 2026 with volume 32,459,600 and a day range of ¥21.00–¥22.00. Activity follows a string of clinical updates and an earnings date set for 30 Jan 2026, keeping investors focused on trial progress and cash runway. Today’s trading interest is driven by biotech sector flows and a tighter 50-day average of ¥21.40 versus a 200-day of ¥24.36, highlighting short-term attention versus longer-term weakness.
Market snapshot for 4564.T stock: price, volume and session context
On 24 Jan 2026 pre-market, 4564.T stock is quoted at ¥21.00, unchanged from the previous close, with a day high of ¥22.00 and day low of ¥21.00. Market cap is approximately ¥7,216,515,054.00, shares outstanding 343,643,574.00, and average volume 53,952,537.00, so today’s 32,459,600.00 trades mark elevated activity in a typically thin mid-cap biotech. The stock sits nearer its 52-week low (¥19.00) than high (¥35.00), which frames intraday moves in the context of recent 3-month weakness of -16.00%.
Why 4564.T stock is most active pre-market: catalysts and news flow
Volume and interest have climbed ahead of the company’s earnings announcement on 30 Jan 2026 and ongoing clinical milestones for vaccine candidate S-588410 and small molecules OTS167/OTS964. Reuters coverage of corporate structure and R&D focus has kept the story visible to institutional and retail traders source. Short-term activity also reflects biotech sector inflows in Japan, where healthcare has outperformed peers in the past year, drawing rotation into clinical-stage names.
Fundamentals and valuation for 4564.T stock: balance sheet and ratios
OncoTherapy Science shows EPS -2.83, PE -7.42, price-to-book 4.06, and cash per share ¥5.26, indicating a capital-heavy R&D profile with negative earnings. The company’s current ratio is 8.63, and debt-to-equity is 0.01, signaling a strong liquidity position but limited profitability. Revenue per share is ¥3.00 and R&D spend accounts for ~53.91% of revenue, consistent with a development-stage biotech funding clinical programs.
Meyka AI rating and technicals for 4564.T stock: model score and indicators
Meyka AI rates 4564.T with a score out of 100: 65.52 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show short-term strength with RSI 68.81, MACD histogram 0.40, Bollinger middle ¥21.05, and CCI 277.90 suggesting overbought momentum but ADX 14.99 indicates no dominant trend. Traders should weigh momentum against limited analyst coverage and mixed fundamentals.
Trading setup and risks for 4564.T stock: liquidity, volatility and catalysts
Expect higher intraday volatility; ATR is ¥1.54 and volume remains elevated versus the 50-day average, so price gaps on news are possible. Key short-term catalysts include the earnings release on 30 Jan 2026 and clinical data updates; failure to show progress could push price toward the ¥19.00 52-week low. Longer-term risks include persistent negative earnings, high R&D burn, and thin institutional coverage despite solid cash reserves.
Valuation and outlook for 4564.T stock: forecasts and price targets
Meyka AI’s forecast model projects a monthly target ¥28.51, a 12‑month projection ¥18.22, and a 3‑year projection ¥14.21, reflecting short-term upside on positive trial news but longer-term downside if approvals stall. Given current ¥21.00, the model implies a +35.77% upside to the monthly target and a -13.24% downside to the 12‑month projection. Analysts tracking biotech comparables focus on trial readouts, partnership deals, and cash runway when setting price targets.
Final Thoughts
4564.T stock trades at ¥21.00 pre-market on JPX on 24 Jan 2026 with heightened activity ahead of an earnings date on 30 Jan 2026. The company has a development-stage biotech profile: solid liquidity (current ratio 8.63), negative EPS (-2.83), and a price-to-book 4.06. For traders, the short-term opportunity is event-driven; Meyka AI’s short-term model calls for a monthly target of ¥28.51 (+35.77%), while the 12‑month projection is ¥18.22 (-13.24%). Our grade (B, HOLD) reflects balanced near-term momentum and structural risk. Forecasts are model-based projections and not guarantees; monitor the Jan 30 earnings and any clinical updates closely, as those outcomes will likely determine whether the stock follows the higher monthly path or reverts toward our 12‑month projection. Meyka AI provides this as an AI-powered market analysis platform insight, not investment advice.
FAQs
What drives volume in 4564.T stock today?
Pre-market interest in 4564.T stock is driven by an upcoming earnings announcement on 30 Jan 2026 and clinical trial milestones, plus Reuters coverage and sector rotation into biotech names.
What are the key financials to watch for 4564.T stock?
Watch EPS (-2.83), cash per share (¥5.26), price-to-book (4.06) and R&D spending at about 54% of revenue; these metrics signal funding strength but negative profitability for 4564.T stock.
How should traders use Meyka AI forecasts for 4564.T stock?
Use Meyka AI’s monthly target (¥28.51) as an event-driven upside scenario and the 12‑month projection (¥18.22) as a cautionary baseline; forecasts are model-based and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
